These gatherings are about more than just sessions, they are about peer-to-peer learning, understanding the common pitfalls and opportunities Australian biotech and medtech companies face, and hearing expert guidance on the practical realities of translation and commercialisation.
A big thank you to our Impact Partners Roche Diagnostics Australia and CSL for their ongoing support of this cohort.
Ben Robinson from Roche Diagnostics Australia hosted us at their North Ryde headquarters on the first day, giving the cohort a behind-the-scenes view of their capabilities, history, and exciting work soon to be available to patients.
The cohort also heard from inspiring success stories, including Kinoxis Therapeutics co-founder Michael Kassiou, and Synchron’s Amos Meltzer, highlighting what it takes to move from early-stage research to global impact.
The following day at Cicada Innovations, we explored practical topics for drug and device commercialisation, from clinical evidence generation and trial strategy with Rebecca Tunstall (Prescient Therapeutics), Jeremy Gale, David Fuller (Dimerix) sharing their extensive big pharma and local biotech clinical trial experience, alongside clinical operations excellence insights from Robin Hansen (Molecule2Market) and Stefan Czyniewski (Mobius Medical), manufacturing and supply chain risk (Hebbat Manhy, Cochlear), regulatory requirements with (David Batka, Adjutor Healthcare) health economics and reimbursement with Bonny Parkinson and Alicia Norman (Macquarie University Centre for the Health Economy). Dr Mana Liao shared some insights into the Industry Growth Program. It reinforces that translating innovation into patient benefit requires a whole-of-system view.
These two days highlighted why bringing industry, innovators, and experts together is so valuable: the cohort left not only with knowledge, but with new or deepened relationships, shared learnings, and inspiration to navigate the challenging path from bench to bedside.
We’re excited to continue supporting these companies as they progress their promising drugs and medical devices for cardiovascular disease and diabetes, with the aim of improving outcomes for patients, carers, and communities.
